Home/Filings/4/0000950170-24-040302
4//SEC Filing

Roth David 4

Accession 0000950170-24-040302

CIK 0001556263other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 4:58 PM ET

Size

14.3 KB

Accession

0000950170-24-040302

Insider Transaction Report

Form 4
Period: 2024-03-31
Roth David
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-03-31+2,0002,000 total
  • Sale

    Common Stock

    2024-04-02$4.98/sh150$74710,451 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-312,0004,000 total
    Common Stock (2,000 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-3113,33326,667 total
    Common Stock (13,333 underlying)
  • Exercise/Conversion

    Common Stock

    2024-03-31+13,33315,333 total
  • Tax Payment

    Common Stock

    2024-04-01$5.12/sh4,732$24,22810,601 total
Footnotes (7)
  • [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
  • [F2]Represents shares used to cover tax withholding upon the release of restricted stock units.
  • [F3]The sale was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  • [F4]The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.97 to $5.02, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F5]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
  • [F6]Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
  • [F7]Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.

Documents

1 file

Issuer

Syros Pharmaceuticals, Inc.

CIK 0001556263

Entity typeother

Related Parties

1
  • filerCIK 0001599014

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 4:58 PM ET
Size
14.3 KB